Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lactitol

FDA-approved product (for solution, oral), marketed as Pizensy.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Lactitol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Constipation
  • Constipation disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Osmotically acting laxatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Lactitol, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA21.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis28.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lactitol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lactitol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

    NCT01148017 · start 2010-07

    Registered record
    Registry ID
    NCT01148017
    Conditions
    Meningococcal Meningitis
    Interventions
    Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-07
    Completion
    2013-04
    Enrolment
    433

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningococcal Meningitis
    InterventionMeningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
    PhasePhase 3
    Registry statusCompleted

  • One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

    NCT01139021 · start 2010-06

    Registered record
    Registry ID
    NCT01139021
    Conditions
    Meningococcal Disease
    Interventions
    rMenB+OMV NZ
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-06
    Completion
    2011-09
    Enrolment
    508

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningococcal Disease
    InterventionrMenB+OMV NZ
    PhasePhase 3
    Registry statusCompleted

  • A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

    NCT01116440 · start 2010-04-15

    Registered record
    Registry ID
    NCT01116440
    Conditions
    Pelvic Pain Associated With Refractory Endometriosis
    Interventions
    BGS649; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-04-15
    Completion
    2012-03-21
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPelvic Pain Associated With Refractory Endometriosis
    InterventionBGS649; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon

    NCT01845701 · start 2010-03

    Registered record
    Registry ID
    NCT01845701
    Conditions
    Malaria
    Interventions
    Artesunate-Amodiaquine; Dihydroartemisinine-Piperaquine; Artemether-lumefantrine combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03
    Completion
    2015-04
    Enrolment
    720

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtesunate-Amodiaquine; Dihydroartemisinine-Piperaquine; Artemether-lumefantrine combination
    PhasePhase 3
    Registry statusCompleted

  • Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

    NCT01027351 · start 2010-01

    Registered record
    Registry ID
    NCT01027351
    Conditions
    Meningococcal Disease
    Interventions
    Meningococcal (group B) multicomponent recombinant adsorbed vaccine.; Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-01
    Completion
    2012-05
    Enrolment
    163

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningococcal Disease
    InterventionMeningococcal (group B) multicomponent recombinant adsorbed vaccine.; Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)
    PhasePhase 2
    Registry statusCompleted

  • Non-malarial Febrile Illness in Children in Areas of Perennial Malaria Transmission

    NCT01043744 · start 2010-01

    Registered record
    Registry ID
    NCT01043744
    Conditions
    Malaria; Non-malarial Febrile Illness
    Interventions
    Artemether-Lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-01
    Completion
    2011-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Non-malarial Febrile Illness
    InterventionArtemether-Lumefantrine
    PhaseNot applicable
    Registry statusCompleted

  • Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza

    NCT01066169 · start 2009-11

    Registered record
    Registry ID
    NCT01066169
    Conditions
    HIV
    Interventions
    Foceteria® (Novartis)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-02
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionFoceteria® (Novartis)
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

    NCT00978120 · start 2009-10

    Registered record
    Registry ID
    NCT00978120
    Conditions
    H1N1 Influenza Virus
    Interventions
    H1N1 vaccine high dose; H1N1 vaccine low dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-10
    Completion
    2010-09
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionH1N1 Influenza Virus
    InterventionH1N1 vaccine high dose; H1N1 vaccine low dose
    PhasePhase 2
    Registry statusCompleted

  • Novel Interventions in HIV-1 Infection

    NCT01130376 · start 2009-09

    Registered record
    Registry ID
    NCT01130376
    Conditions
    HIV-1 Infection
    Interventions
    GTU-MultiHIV B clade vaccine1mg; Interleukin-2; GM-CSF; Growth Hormone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2009-09
    Completion
    2011-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionGTU-MultiHIV B clade vaccine1mg; Interleukin-2; GM-CSF; Growth Hormone
    PhasePhase 1
    Registry statusTerminated

  • Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)

    NCT00868465 · start 2009-04

    Registered record
    Registry ID
    NCT00868465
    Conditions
    Uncomplicated Malaria
    Interventions
    Artemether-Lumefantrine; Dihydroartemisinin-piperaquine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-04
    Completion
    2010-05
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Malaria
    InterventionArtemether-Lumefantrine; Dihydroartemisinin-piperaquine
    PhaseNot applicable
    Registry statusCompleted

  • L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients

    NCT00587418 · start 2008-11

    Registered record
    Registry ID
    NCT00587418
    Conditions
    Liver Transplant Recipients
    Interventions
    L-arginine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-11
    Completion
    2012-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant Recipients
    InterventionL-arginine; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)

    NCT01129622 · start 2008-10

    Registered record
    Registry ID
    NCT01129622
    Conditions
    Breast Cancer
    Interventions
    letrozole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2010-09
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionletrozole
    PhasePhase 2
    Registry statusCompleted

  • Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination

    NCT01232075 · start 2008-09

    Registered record
    Registry ID
    NCT01232075
    Conditions
    Infertility
    Interventions
    Extended letrozole regimen; Clomiphene citrate regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-09
    Completion
    2010-12
    Enrolment
    214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionExtended letrozole regimen; Clomiphene citrate regimen
    PhasePhase 2
    Registry statusCompleted

  • B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

    NCT00488683 · start 2007-07

    Registered record
    Registry ID
    NCT00488683
    Conditions
    Meningococcal Disease
    Interventions
    MenACWY-CRM; DTaP-Hib-IPV; PCV; MMR; Hib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-07
    Completion
    2009-06
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningococcal Disease
    InterventionMenACWY-CRM; DTaP-Hib-IPV; PCV; MMR +1 more
    PhasePhase 2
    Registry statusCompleted

  • Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

    NCT00560313 · start 2007-07

    Registered record
    Registry ID
    NCT00560313
    Conditions
    Meningococcal Disease
    Interventions
    Men ACWY CRM; 4CMenB
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-07
    Completion
    2009-11
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningococcal Disease
    InterventionMen ACWY CRM; 4CMenB
    PhasePhase 2
    Registry statusCompleted